Curated News
By: NewsRamp Editorial Staff
March 25, 2026
VolitionRx's Liquid Biopsy Shows 95% Accuracy in Early Cancer Detection
TLDR
- VolitionRx's Capture-Seq technology offers investors early access to a $36 billion market with high-accuracy cancer detection capabilities for potential licensing partnerships.
- VolitionRx's Capture-Seq technology enriches circulating tumor DNA, achieving 93-96% sensitivity and 95% specificity in detecting early-stage cancers through blood-based analysis.
- This technology enables earlier cancer detection, potentially saving lives and improving patient outcomes through less invasive monitoring and treatment.
- A simple blood test can now detect early-stage cancers with over 95% accuracy using epigenetic analysis of circulating tumor DNA.
Impact - Why it Matters
This development represents a potential paradigm shift in cancer screening and early detection. Liquid biopsies like VolitionRx's Capture-Seq technology could make cancer detection more accessible, less invasive, and potentially more affordable than traditional methods like imaging scans or tissue biopsies. Early detection is crucial in cancer treatment—cancers caught at stage I or II typically have dramatically better survival rates and treatment outcomes than those detected later. For patients, this could mean earlier interventions, less aggressive treatments, and significantly improved quality of life. For healthcare systems, widespread adoption of such technology could reduce late-stage cancer treatment costs and improve population health outcomes. The technology's potential applications in multi-cancer early detection and minimal residual disease monitoring could transform how we approach cancer surveillance and treatment response assessment.
Summary
VolitionRx (NYSE American: VNRX) has announced groundbreaking proof-of-concept data for its Capture-Seq liquid biopsy technology, demonstrating remarkable accuracy in early cancer detection. In a blinded validation study involving 81 subjects, the technology achieved over 95% sensitivity for stage I and II cancers with 95% specificity, with detection rates reaching 94% for stage I and 96% for stage II cancers. This breakthrough positions VolitionRx at the forefront of the epigenetics revolution, with its technology designed to enrich and purify circulating tumor DNA for analysis, potentially transforming how cancers are detected and monitored.
The company's Capture-Seq technology targets a massive $36 billion total addressable market and is currently the subject of discussions with potential licensing and diagnostic partners to accelerate development and commercialization. Volition, a multi-national company with research centers in Belgium, the U.S., and London, is dedicated to saving lives through earlier detection of life-altering diseases. Their blood tests aim to be simple, easy to use, and cost-effective, potentially prolonging patients' lives and improving their quality of life through early intervention.
This announcement was distributed through InvestorWire, a specialized communications platform within the Dynamic Brand Portfolio at IBN, which provides advanced wire-grade press release syndication and comprehensive corporate communications solutions. The news highlights Volition's commitment to advancing cancer detection technology that could fundamentally change patient outcomes and represents a significant milestone in the company's journey toward commercialization and market adoption.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, VolitionRx's Liquid Biopsy Shows 95% Accuracy in Early Cancer Detection
